Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
DISASTERS AVERTED — Near Miss Case Studies
Dosing Error Due to Misinterpretation
TOP STORIES — Diabetes News and Research
Here We Go Again: The Low-Carb vs. High-Carb and Training Debate
By Sheri Colberg, PhD
Semglee, a Biosimilar Insulin to Glargine, Receives FDA Approval
ADA 81st Symposium: The Onset of T2D in Youth and Long-Term Complications
MOST POPULAR ARTICLES OF THE MONTH
#1 ADA 2021: A Promising Future for Tirzepatide
#2 ADA 81st Symposium: Tirzepatide a Novel GIP/GLP-1 Agonist-Current Update
#3 Benefits for Patients with Type 1 Diabetes Using the New Omnipod® 5
Letter from the Editor
One thing about having virtual conferences is that you can easily measure the attendance of any presentation; live and revisited. This year the most viewed presentation was from our own Diabetes and Physical Activity expert, Dr. Sheri Colberg.
Dr. Colberg delivered a program on the differences between low and high carb eating for athletes, both with and without diabetes. If you follow her on our website you know that she has addressed this topic before. This week she has taken the best of her entire presentation and prepared a clear, concise article for you to learn from.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief
DISASTERS AVERTED — Near Miss Case Studies
When reviewing the medical record of a hospital patient before meeting with her for a diabetes consult, I noted that the doctor had ordered 46 units of Lantus to be given daily at bedtime….
TOP STORIES — Diabetes News and Research
By Sheri Colberg, PhD
Who knew I’d be talking about carbohydrate intake and being active for the third time this year, but here we go again! Unfortunately, a lot of confusion still exists related to the practice known as “carb loading” as well. Do you need to do it? Should you? How do you know?
With the introduction of this new biosimilar insulin, patients with diabetes will have the opportunity to have easier and broader access to insulin therapy, and a more affordable option than those already on the market.
Pediatric patients with T2D have accelerated onset of hypertension, dyslipidemia, kidney disease, nerve disease, and diabetic retinopathy.